Posted by Michael Wonder on 13 Nov 2019
Viracta receives fast track designation for nanatinostat combination for the treatment of EBV-associated lymphomas
12 November 2019 - Viracta Therapeutic, announced today that the U.S. FDA has granted fast track designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies.
The Company previously announced interim data from the Phase 1b portion of an ongoing Phase 1b/2a clinical trial of nanatinostat in combination with the antiviral valganciclovir in patients with relapsed/refractory EBV-associated lymphomas. These data were provided to the FDA in support of the fast track designation request.
Updated clinical data will be presented during an oral session at the American Society of Hematology meeting in Orlando, Florida on 8 December 2019.
